Abstract
Differentiated thyroid carcinoma is the most common malignancy in endocrinology. When detected early, its prognosis is very favorable.
Its treatment and subsequent follow up remain based on the following key pharmaceuticals: radioiodine 131I and thyroid hormones. In recent years, therapeutic and diagnostic capabilities have been enhanced with recombinant human TSH (rhTSH) inducing phase controlled hypothyroidism.
Radioiodine refractory cancers can be treated with gene targeted therapy using tyrosine kinase inhibitors. The article gives an overview of the new drugs, making this treatment possible in Czech Republic.